Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01764061 · ClinicalTrials.gov registry record
Clinical Investigational Protocol for 2 RBC Single Unit Recovery on MCS®+ 8150 Using LN832 Disposable Sets (US)
A clinical trial, sponsored by Haemonetics Corporation.
- Completed
- Registry status
- 60
- Enrollment target
NCT01764061 is a clinical trial that has completed, run by Haemonetics Corporation. The registered enrollment target is 60 participants.
The verdict
NCT01764061 has completed, sponsored by Haemonetics Corporation.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to validate that single units of RBCs collected by the Haemonetics MCS®+ 8150 system using LN832 disposable sets during an interrupted double red cell collection protocol meet all in vitro FDA requirements for non-leukoreduced red blood cells, and to provide data to support the 510(k) clearance of the MCS®+ 8150 system using LN832 disposable sets for this intended use.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2013-01 |
| Est. Completion | 2013-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01764061
The ClinicalTrials.gov registry entry for NCT01764061 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Haemonetics Corporation, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01764061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01764061 about?
NCT01764061 is a clinical study titled "Clinical Investigational Protocol for 2 RBC Single Unit Recovery on MCS®+ 8150 Using LN832 Disposable Sets (US)". The purpose of this study is to validate that single units of RBCs collected by the Haemonetics MCS®+ 8150 system using LN832 disposable sets during an interrupted double red cell collection protocol meet all in vitro FDA requirements for non-leukoreduced red blood cells, and to provide data to supp...
What is the current status of trial NCT01764061?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2013-01. Estimated completion is 2013-09.
Who is sponsoring clinical trial NCT01764061?
This trial is sponsored by Haemonetics Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.